

NEUROCRINE BIOSCIENCES INC
 Form 3
 January 17, 2008

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Â Grigoriadis Dimitri E. (Last) (First) (Middle) NEUROCRINE BIOSCIENCES, INC., Â 12790 EL CAMINO REAL (Street) SAN DIEGO, Â CA Â 92130 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 01/10/2008	3. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC [NBIX]	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below) Vice President, Research	5. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
---	--	---	--	--	---

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	4,358	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
---	---	--	---	---	--

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Employee Stock Option (right to buy) ⁽¹⁾	09/19/1998	08/19/2008	Common Stock	7,500	\$ 6.5	D	Â
Employee Stock Option (right to buy) ⁽²⁾	07/01/1999	06/01/2009	Common Stock	4,000	\$ 4.875	D	Â
Employee Stock Option (right to buy) ⁽³⁾	09/26/2007	07/23/2013	Common Stock	937	\$ 10.9	D	Â
Employee Stock Option (right to buy) ⁽³⁾	09/26/2007	09/26/2013	Common Stock	4,737	\$ 10.9	D	Â
Employee Stock Option (right to buy) ⁽³⁾	09/26/2007	06/22/2010	Common Stock	3,750	\$ 10.9	D	Â
Employee Stock Option (right to buy) ⁽³⁾	09/26/2007	06/26/2011	Common Stock	3,125	\$ 10.9	D	Â
Employee Stock Option (right to buy) ⁽³⁾	09/26/2007	07/05/2012	Common Stock	3,250	\$ 10.9	D	Â
Employee Stock Option (right to buy) ⁽³⁾	09/26/2007	09/05/2012	Common Stock	10,125	\$ 10.9	D	Â
Restricted Stock Units	Â ⁽⁴⁾	Â ⁽⁴⁾	Common Stock	16,667	\$ ⁽⁵⁾	D	Â
Restricted Stock Units	Â ⁽⁶⁾	Â ⁽⁶⁾	Common Stock	10,000	\$ ⁽⁵⁾	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Grigoriadis Dimitri E. NEUROCRINE BIOSCIENCES, INC. 12790 EL CAMINO REAL SAN DIEGO, CA 92130	Â	Â	Â Vice President, Research	Â

Signatures

Margaret E. Valeur-Jensen, By Power of Attorney

01/17/2008

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents option of which one forty-eighth (1/48) of the shares underlying the option becomes vested and exercisable on September 19, 1998 and an additional one forty-eighth (1/48) of the shares underlying the option becomes vested and exercisable each month thereafter.

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 3

- (2) Represents option of which one forty-eighth (1/48) of the shares underlying the option becomes vested and exercisable on July 1, 1999 and an additional one forty-eighth (1/48) of the shares underlying the option becomes vested and exercisable each month thereafter.
- (3) This option is exercisable in three annual installments. The first installment became exercisable on September 26, 2007, and the next two installments become exercisable on September 26, 2008 and September 26, 2009.
- (4) The restricted stock units vest in three annual installments. The first installment became exercisable on October 26, 2007, and the next two installments become exercisable on September 26, 2008 and September 26, 2009.
- (5) Each restricted stock unit represents a contingent right to receive one share of NBIX common stock.
- (6) The restricted stock units vest in three annual installments beginning February 3, 2008 and the next two installments become exercisable on January 3, 2009 and January 3, 2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.